The dopamine D3/D2 agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1, 4-oxazin-9-ol)] protects against acute and cocaine-kindled seizures in mice: Further evidence for the involvement of D3 receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 326, Issue 3, 2008, Pages 930-938

  Witkin, Jeffrey M ^a   Levant, B ^b   Zapata, A ^c   Kaminski, R ^c,d   Gasior, M ^c,e  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^d UCB PHARMA   (Belgium)

^e CEPHALON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; 4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; COCAINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; PENTETRAZOLE; 3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H (1)BENZOPYRANO(4,3 B) 1,4 OXAZIN 9 OL; 3,4,4A,10B-TETRAHYDRO-4-PROPYL-2H,5H-(1)BENZOPYRANO(4,3-B)-1,4-OXAZIN-9-OL; BENZOPYRAN DERIVATIVE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; OXAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BIPOLAR DEPRESSION; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG RECEPTOR BINDING; KINDLING; KNOCKOUT MOUSE; LETHALITY; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SCHIZOPHRENIA; SEIZURE; WILD TYPE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; DRUG POTENTIATION; MOUSE MUTANT; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN BINDING;

ANIMALS; BENZOPYRANS; COCAINE; DOPAMINE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXAZINES; PROTEIN BINDING; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SEIZURES;

EID: 49949097407     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.139212     Document Type: Article

References (50)

1. Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park BH, Gauda EB, Lee EJ, Cool MH, Sibley DR, et al. (1996) A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci U S A 93:1945-1949.
2. Acri JB, Carter SR, Alling K, Geter-Douglass B, Dijkstra D, Wikström H, Katz JL, and Witkin JM (1995) Assessment of cocaine-like discriminative stimulus effects of dopamine D3 receptor ligands. Eur J Pharmacol 281:R7-R9.
3. 3 dopamine receptor, in rat brain: a receptor binding and quantitative autoradiographic study. Neuropsychopharmacology 18:305-316.
4. Bordet R, Ridray S, Carboni S, Diaz J, Sokoloff P, and Schwartz JC (1997) Induction of dopamine D3 receptor as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci U S A 94:3363-3367.
5. Boulay D, Depoortere R, Rostene W, Perrault G, and Sanger DJ (1999) Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice. Neuropharmacology 38:555-565.
6. Caine SB and Koob GF (1993) Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science 260:1814-1816.
7. Chaperon F, Tricklebank MD, Unger L, and Neijt HC (2003) Evidence for regulation of body temperature in rats by dopamine D2 receptor and possible influence of D1 but not D3 and D4 receptors. Neuropharmacology 44:1047-1053.
8. Chiang YC, Chen PC, and Chen JC (2003) D(3) dopamine receptors are downregulated in amphetamine sensitized rats and their putative antagonists modulate the locomotor sensitization to amphetamine. Brain Res 972:159-167.
9. Collins GT, Newman AH, Grundt P, Rice KC, Husbands SM, Chauvignac C, Chen J, Wang S, and Woods JH (2007) Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Psychopharmacology 193:159-170.
10. Collins GT, Witkin JM, Newman AH, Svensson KA, Grundt P, Cao J, and Woods JH (2005) Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. J Pharmacol Exp Ther 314:310-319.
11. Derlet RW and Albertson TE (1989) Emergency department presentation of cocaine intoxication. Ann Emerg Med 18:182-186.
12. Dhuna A, Pascual-Leone A, Langendorf F, and Anderson DC (1991) Epileptogenic properties of cocaine in humans. Neurotoxicology 12:621-626.
13. Gasior M, Beekman M, Carter RB, Goldberg SR, and Witkin JM (1998) Antiepileptogenic effects of the novel synthetic neuroactive steroid, ganaxolone, against pentylenetetrazol-induced kindled seizures: comparison with diazepam and valproate. Drug Dev Res 44:21-33.
14. Gasior M, Carter RB, Goldberg SR, and Witkin JM (1997) Anticonvulsant and behavioral effects of neuroactive-steroids alone and in conjunction with diazepam. J Pharmacol Exp Ther 282:543-553.
15. Goldstein RZ and Volkow ND (2002) Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 159:1642-1652.
16. Guo N, Vincent SR, and Fibiger HC (1998) Phenotypic characterization of neuroleptic-sensitive neurons in the forebrain: contrasting targets of haloperidol and clozapine. Neuropsychopharmacology 9:133-145.
17. Gurevich EV, Bordelon Y, Shapiro RM, Arnold SE, Gur RE, and Joyce JN (1997) Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch Gen Psychiatry 54:225-232.
18. Joyce JN and Millan MJ (2007) Dopamine D3 receptor agonists for protection and repair in Parkinson's disease. Curr Opin Pharmacol 7:100-105.
19. Joyce JN, Woolsey C, Ryoo H, Borwege S, and Hagner D (2004) Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor. BMC Biol 2:22.
20. Kelly MA, Rubinstein M, Phillips TJ, Lessov CN, Burkhart-Kasch S, Zhang G, Bunzow JR, Fang Y, Gerhardt GA, Grandy DK, et al. (1998) Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations. J Neurosci 18:3470-3479.
21. Le Foll B, Diaz J, and Sokoloff P (2003a) Increased dopamine D3 receptor expression accompanying behavioral sensitization to nicotine in rats. Synapse 47:176-183.
22. Le Foll B, Schwartz JC, and Sokoloff P (2003b) Disruption of nicotine conditioning by dopamine D(3) receptor ligands. Mol Psychiatry 8:225-230.
23. Levant B (1997) The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol Rev 49:231-252.
24. Lieberman JA, Sheitman BB, and Kinon BJ (1997) Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology 17:205-229.
25. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, Keefe RS, Green AI, Gur RE, McEvoy J, et al. (2005) Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 62:361-370.
26. Löscher W, Honack D, Fassbender CP, and Nolting B (1991) The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res 8:171-189.
27. Löscher W and Schmidt D (1988) Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 2:145-181.
28. McNamara JO, Bonhaus DW, and Shin C (1993) The kindling model of epilepsy, in Epilepsy: Models, Mechanisms, and Concepts (Schwartzkroin PA ed) pp 27-47, Cambridge University Press, Cambridge, UK.
29. Miller KA, Witkin JM, Ungard JT, and Gasior M (2000) Pharmacological and behavioral characterization of cocaine-kindled seizures in mice. Psychopharmacology 148:74-82.
30. Perachon S, Betancur C, Pilon C, Rostène W, Schwartz JC, and Sokoloff P (2000) Role of dopamine D3 receptors in thermoregulation: a reappraisal. Neuroreport 11:221-225.
31. Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, Schwartz JC, Everitt BJ, and Sokoloff P (1999) Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 400:371-375.
32. Post RM and Weiss SR (1989) Sensitization, kindling, and anticonvulsants in mania. J Clin Psychiatry 50 (Suppl):23-30.
33. Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY, Boyfield I, Branch CL, Cilia J, Coldwell MC, et al. (2000) Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 294:1154-1165.
34. Reid MS, Hsu K Jr, and Berger SP (1997) Cocaine and amphetamine preferentially stimulate glutamate release in the limbic system: studies on the involvement of dopamine. Synapse 27:95-105.
35. Richtand NM, Welge JA, Levant B, Logue AD, Hayes S, Pritchard LM, Geracioti TD, Coolen LM, and Berger SP (2003) Altered behavioral response to dopamine D3 receptor agonists 7-OH-DPAT and PD 128907 following repetitive amphetamine administration. Neuropsychopharmacology 28:1422-1432.
36. Robertson GS, Lee CJ, Sridhar K, Nakabeppu Y, Cheng M, Wang Y-M, and Caron MG (2004) Clozapine-, but not haloperidol-, induced increases in ΔFosB-like immunoreactivity are completely blocked in the striatum of mice lacking D3 dopamine receptors. Eur J Neurosci 20:3189-3194.
37. Robinson SE, Kunko PM, Smith JA, Wallace MJ, Mo Q, and Maher JR (1997) Extracellular aspartate concentration increases in nucleus accumbens after cocaine sensitization. Eur J Pharmacol 319:31-36.
38. Sokoloff P, Giros BJ, Martres M-P, Bouthenet ML, and Schwartz J-C (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347:146-151.
39. Spealman RD (1996) Dopamine D3 receptor agonists partially reproduce the discriminative stimulus effects of cocaine in squirrel monkeys. J Pharmacol Exp Ther 278:1128-1137.
40. Staley JK and Mash DC (1996) Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci 16:6100-6106.
41. Substance Abuse and Mental Health Services Administration, Office of Applied Studies (2003) Emergency Department Trends from the Drug Abuse Warning Network, Final Estimates 1995-2002, DAWN Series D-24, DHHS Publication No. (SMA) 03-3780, Department of Health and Human Services, Rockville, MD.
42. Vorel SR, Ashby CR Jr, Paul M, Liu X, Hayes R, Hagan JJ, Middlemiss DN, Stemp G, and Gardner EL (2002) Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. Neuroscience 22:9595-9603.
43. 2 agonist R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4, 3-b]-1,4-oxazin-9-0l [(+)-PD 128,907]. J Pharmacol Exp Ther 308:957-964.
44. 3 receptor agonist, (+)-PD 128,907. Eur J Pharmacol 347:R1-R3.
45. Witkin JM, Gasior M, Heifets B, and Tortella FC (1999) Anticonvulsant efficacy of N-methyl-D-aspartate antagonists against convulsions induced by cocaine. J Pharmacol Exp Ther 289:703-711.
46. Witkin JM and Tortella FC (1991) Modulators of N-methyl-D- aspartate protect against diazepam- or phenobarbital-resistant cocaine convulsions. Life Sci 48: PL51-PL56.
47. Xu M, Koeltzow TE, Cooper DC, Tonegawa S, and White FJ (1999) Dopamine D3 receptor mutant and wild-type mice exhibit identical responses to putative D3 receptor-selective agonists and antagonists. Synapse 31:210-215.
48. Zapata A, Kivell B, Han Y, Javitch JA, Bolan EA, Kuraguntla D, Jaligam V, Oz M, Jayanthi LD, Samuvel DJ, et al. (2007) Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors. J Biol Chem 282:35842-35854.
49. Zapata A and Shippenberg TS (2002) D(3) receptor ligands modulate extracellular dopamine clearance in the nucleus accumbens. J Neurochem 81:1035-1042.
50. Zapata A and Shippenberg TS (2005) Lack of functional D2 receptors prevents the effects of the D3-preferring agonist (+)-PD 128907 on dialysate dopamine levels. Neuropharmacology 48:43-50.